Supplemental treatment of rheumatoid arthritis with natural milk antibodies against enteromicrobes and their toxins

Supplemental treatment of rheumatoid arthritis with natural milk antibodies against enteromicrobes and their toxins - Supplemental treatment of rheumatoid arthritis with natural milk antibodies

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003128

Enrollment

Registered

2010-02-15

Start date

2007-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

Patients receive milk antibody administration for three months with the concurrent treatments. Some patients receive repeated milk antibody treatment after structured treatment interruption. Patients

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with RA whose disease activity was uncontrolled by authentic medications due to drug resistance or complications and risk factors.

Exclusion criteria

Exclusion criteria: Patients with milk allergy

Design outcomes

Primary

Measure	Time frame
ACR response criteria, EULAR response criteria using the 28-joints count disease activity score using ESR (DAS28-ESR) and Evaluation Points, a modified American College of Rheumatology (ACR) criteria	—

Secondary

Measure	Time frame
General health, for conditions such as GI status, appetite, weight gain, activities of daily living (ADL), anemia, fatigue, sleep and daily physical feeling.	—

Countries

Japan

Contacts

Public ContactKou Katayama

Katayama Orthopedic Rheumatology Clinic Department of orthopedic surgery

kou@kata-rheum.or.jp0166-39-1155

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026